Illinois Drug Manufacturers Sue to Block State's Expanded 340B Program

• Pharmaceutical companies sue Illinois Attorney General Kwame Raoul to block state law requiring discounted drugs for all pharmacy providers.
• Lawsuit argues that the Illinois law expands the 340B program requirements in a way that shifts financial burdens onto manufacturers without just compensation.
• Plaintiffs claim that covered entities are gaming the system to maximize their benefits at the expense of manufacturers and patients.
• Illinois law forces manufacturers to provide more 340B priced drugs and profits to hospitals, commercial pharmacies, and third-party administrators than federal law requires.

The plaintiffs argue that this expansion violates the supremacy clause of the Constitution by changing the terms of the 340B program without congressional approval.

A group of pharmaceutical companies, including AbbVie Inc. and Novartis Pharmaceuticals, has sued Illinois Attorney General Kwame Raoul in federal court to block a state law requiring them to send discounted drugs to any pharmacy provider. The lawsuit argues that the state law expands the 340B program requirements in a way that shifts financial burdens onto manufacturers without just compensation. According to the complaint, the Illinois law forces manufacturers to provide more 340B priced drugs and profits to hospitals, commercial pharmacies, and third-party administrators than federal law requires. This, the plaintiffs claim, is a clear example of gaming the system by covered entities to maximize their benefits at the expense of manufacturers and patients.

The 340B program is a federal law that requires drug manufacturers to sell certain drugs at discounted rates for non-profit hospitals and clinics. However, the Illinois law expands this requirement to include commercial pharmacies purporting to work with covered entities. The plaintiffs argue that this expansion violates the supremacy clause of the Constitution by changing the terms of the 340B program without congressional approval. Furthermore, they claim that the patchwork of variable regulation across nearly two dozen states makes it impossible for the federal government to manage compliance with the 340B program.

The lawsuit has significant implications for pharmaceutical manufacturers and their compliance obligations. If the Illinois law is allowed to stand, it could set a precedent for other states to follow suit, creating a complex web of regulations that would be difficult for manufacturers to navigate. Moreover, the expansion of the 340B program could lead to increased costs for manufacturers and reduced revenue without any corresponding public benefit. As one attorney noted, the profits made from the 340B program are often used for purposes unrelated to patient care, such as naming rights deals with sports teams or luxury apartment construction.

Lawyers should watch for potential federal preemption challenges to similar state laws expanding the 340B program, which could impact pharmaceutical manufacturers' compliance obligations and revenue.

Source: Original reporting via Courthouse News